An Open Label, Phase I Dose-finding Study of BI 754111 in Combination with BI 754091 in Patients with Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients with Non-small Cell Lung Cancer and Other Solid Tumors

Protocol No
BI-1381-REFMAL485
Principal Investigator
Ben George
Phase
I
Summary
Both study drugs are medicines that may treat cancer by working with your immune system. The immune system is your bodys natural defense against disease. The immune system sends cells called T-cells throughout your body to detect and fight infections and diseases, such as cancer. For some types of cancer, the T-cells do not work as they should and are prevented from attacking the tumors. The study drugs are antibodies designed to work by blocking 2 different proteins in your T-cells. BI 754111 blocks the protein called LAG-3 (lymphocyte-activation gene 3). BI 754091 blocks the protein called PD-1 (programmed death 1). Blocking LAG-3 and PD-1 allows T-cells and other parts of your immune system to attack tumors. This may shrink tumors and help people live longer. It is thought that by combining the 2 study drugs, they may have more of an effect on cancer cells rather than if they were used alone.
Description
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: